NF-κB and cancer

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Nuclear factor-κB (NF-κB) transcription factors and their signaling pathways have come to the forefront of the cancer field as mechanistic links connecting chronic inflammation and oncogenesis (1). These master transcription factors integrate multiple stimuli and co-ordinate innate and adaptive immune responses involved in acute and chronic inflammation (2). Epidemiological studies which pointed out that chronic inflammation and persistent infections greatly increase the risk of cancers of stomach, colon, and liver first suggested a link between inflammation, the innate immune response, and cancer (3). NF-κB was suggested as the molecular culprit that bridges these pathophysiological states and responses (1). However, establishing the association between NF-κB signaling and oncogenesis has been a challenging task because NF-κB and its activating machinery are rarely mutated in cancer cells in the same way as classical oncogenes (like Ras) or tumor-suppressor genes (like p53). Nonetheless, much evidence has been gathered, both through correlative studies and through direct experimentation, that NF-κB signaling does indeed contribute to cancer development and progression, mainly in inflammation-associated cancers, but also in cancers where underlying chronic inflammation plays little or no role (for example, breast and prostate cancers). The list of human cancers that were found to exhibit constitutive NF-κB activation is long (see Table 29.1). Experimental evidence providing causality for NF-κB signaling in oncogenesis has accumulated over the past several years (4), and will be detailed in this chapter.

Original languageEnglish (US)
Title of host publicationMolecular Oncology: Causes of Cancer and Targets for Treatment
PublisherCambridge University Press
Pages336-352
Number of pages17
ISBN (Print)9781139046947, 9780521876629
DOIs
StatePublished - Jan 1 2015

Fingerprint

Inflammation
Neoplasms
Carcinogenesis
Innate Immunity
Transcription Factors
ras Genes
Adaptive Immunity
Liver Neoplasms
Tumor Suppressor Genes
Causality
Colonic Neoplasms
Stomach Neoplasms
Epidemiologic Studies
Prostatic Neoplasms
Breast Neoplasms
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Naugler, W. S., & Karin, M. (2015). NF-κB and cancer. In Molecular Oncology: Causes of Cancer and Targets for Treatment (pp. 336-352). Cambridge University Press. https://doi.org/10.1017/CBO9781139046947.030

NF-κB and cancer. / Naugler, Willscott (Scott); Karin, Michael.

Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, 2015. p. 336-352.

Research output: Chapter in Book/Report/Conference proceedingChapter

Naugler, WS & Karin, M 2015, NF-κB and cancer. in Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, pp. 336-352. https://doi.org/10.1017/CBO9781139046947.030
Naugler WS, Karin M. NF-κB and cancer. In Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press. 2015. p. 336-352 https://doi.org/10.1017/CBO9781139046947.030
Naugler, Willscott (Scott) ; Karin, Michael. / NF-κB and cancer. Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, 2015. pp. 336-352
@inbook{5c7d145936314d1d8f8557a89869353c,
title = "NF-κB and cancer",
abstract = "Introduction Nuclear factor-κB (NF-κB) transcription factors and their signaling pathways have come to the forefront of the cancer field as mechanistic links connecting chronic inflammation and oncogenesis (1). These master transcription factors integrate multiple stimuli and co-ordinate innate and adaptive immune responses involved in acute and chronic inflammation (2). Epidemiological studies which pointed out that chronic inflammation and persistent infections greatly increase the risk of cancers of stomach, colon, and liver first suggested a link between inflammation, the innate immune response, and cancer (3). NF-κB was suggested as the molecular culprit that bridges these pathophysiological states and responses (1). However, establishing the association between NF-κB signaling and oncogenesis has been a challenging task because NF-κB and its activating machinery are rarely mutated in cancer cells in the same way as classical oncogenes (like Ras) or tumor-suppressor genes (like p53). Nonetheless, much evidence has been gathered, both through correlative studies and through direct experimentation, that NF-κB signaling does indeed contribute to cancer development and progression, mainly in inflammation-associated cancers, but also in cancers where underlying chronic inflammation plays little or no role (for example, breast and prostate cancers). The list of human cancers that were found to exhibit constitutive NF-κB activation is long (see Table 29.1). Experimental evidence providing causality for NF-κB signaling in oncogenesis has accumulated over the past several years (4), and will be detailed in this chapter.",
author = "Naugler, {Willscott (Scott)} and Michael Karin",
year = "2015",
month = "1",
day = "1",
doi = "10.1017/CBO9781139046947.030",
language = "English (US)",
isbn = "9781139046947",
pages = "336--352",
booktitle = "Molecular Oncology: Causes of Cancer and Targets for Treatment",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - NF-κB and cancer

AU - Naugler, Willscott (Scott)

AU - Karin, Michael

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction Nuclear factor-κB (NF-κB) transcription factors and their signaling pathways have come to the forefront of the cancer field as mechanistic links connecting chronic inflammation and oncogenesis (1). These master transcription factors integrate multiple stimuli and co-ordinate innate and adaptive immune responses involved in acute and chronic inflammation (2). Epidemiological studies which pointed out that chronic inflammation and persistent infections greatly increase the risk of cancers of stomach, colon, and liver first suggested a link between inflammation, the innate immune response, and cancer (3). NF-κB was suggested as the molecular culprit that bridges these pathophysiological states and responses (1). However, establishing the association between NF-κB signaling and oncogenesis has been a challenging task because NF-κB and its activating machinery are rarely mutated in cancer cells in the same way as classical oncogenes (like Ras) or tumor-suppressor genes (like p53). Nonetheless, much evidence has been gathered, both through correlative studies and through direct experimentation, that NF-κB signaling does indeed contribute to cancer development and progression, mainly in inflammation-associated cancers, but also in cancers where underlying chronic inflammation plays little or no role (for example, breast and prostate cancers). The list of human cancers that were found to exhibit constitutive NF-κB activation is long (see Table 29.1). Experimental evidence providing causality for NF-κB signaling in oncogenesis has accumulated over the past several years (4), and will be detailed in this chapter.

AB - Introduction Nuclear factor-κB (NF-κB) transcription factors and their signaling pathways have come to the forefront of the cancer field as mechanistic links connecting chronic inflammation and oncogenesis (1). These master transcription factors integrate multiple stimuli and co-ordinate innate and adaptive immune responses involved in acute and chronic inflammation (2). Epidemiological studies which pointed out that chronic inflammation and persistent infections greatly increase the risk of cancers of stomach, colon, and liver first suggested a link between inflammation, the innate immune response, and cancer (3). NF-κB was suggested as the molecular culprit that bridges these pathophysiological states and responses (1). However, establishing the association between NF-κB signaling and oncogenesis has been a challenging task because NF-κB and its activating machinery are rarely mutated in cancer cells in the same way as classical oncogenes (like Ras) or tumor-suppressor genes (like p53). Nonetheless, much evidence has been gathered, both through correlative studies and through direct experimentation, that NF-κB signaling does indeed contribute to cancer development and progression, mainly in inflammation-associated cancers, but also in cancers where underlying chronic inflammation plays little or no role (for example, breast and prostate cancers). The list of human cancers that were found to exhibit constitutive NF-κB activation is long (see Table 29.1). Experimental evidence providing causality for NF-κB signaling in oncogenesis has accumulated over the past several years (4), and will be detailed in this chapter.

UR - http://www.scopus.com/inward/record.url?scp=84954183684&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954183684&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139046947.030

DO - 10.1017/CBO9781139046947.030

M3 - Chapter

SN - 9781139046947

SN - 9780521876629

SP - 336

EP - 352

BT - Molecular Oncology: Causes of Cancer and Targets for Treatment

PB - Cambridge University Press

ER -